<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit

Program

KU-Authors

Organization Authors

Co-Authors

Yalman, Deniz

Date

Language

Type

Embargo Status

N/A

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

The standard treatment for operable, early stage non-small cell lung cancer (NSCLC) is surgical resection, usually lobectomy, with mediastinal lymph node sampling or dissection. However, significant surgical toxicity had been noted in these patients with 90-day mortality rates exceeding 30-day rates. There is also a risk of disease recurrence ranging from 6% to 10% per person-year during the first 4 years after surgery as stated by Lou et al. after an analysis of 1,300 patients who underwent surgery.

Source

Publisher

AME Publishing Company

Citation

item.page.haspartof

Source

Annals of Translational Medicine

item.page.ispartofseries

item.page.edition

DOI

10.3978/j.issn.2305-5839.2015.06.23

item.page.datauri

item.page.link

Rights

N/A

Copyrights Note

Rights and licensing

N/A

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators